HUE031924T2 - Peptidek, konjugátumok és eljárás oltóanyag immunogenitásának fokozására - Google Patents

Peptidek, konjugátumok és eljárás oltóanyag immunogenitásának fokozására Download PDF

Info

Publication number
HUE031924T2
HUE031924T2 HUE11712343A HUE11712343A HUE031924T2 HU E031924 T2 HUE031924 T2 HU E031924T2 HU E11712343 A HUE11712343 A HU E11712343A HU E11712343 A HUE11712343 A HU E11712343A HU E031924 T2 HUE031924 T2 HU E031924T2
Authority
HU
Hungary
Prior art keywords
lys
ile
leu
asn
ser
Prior art date
Application number
HUE11712343A
Other languages
English (en)
Inventor
Ferdinand Antonius Ossendorp
Cornelis Joseph Maria Melief
Jan Wouter Drijfhout
Original Assignee
Academisch Ziekenhuis Leiden
Stichting Technische Wetenschappen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden, Stichting Technische Wetenschappen filed Critical Academisch Ziekenhuis Leiden
Publication of HUE031924T2 publication Critical patent/HUE031924T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (7)

  1. FËP I IOEK, «IMJÜOÀttîËîfâKM ElJitó ÖETÖAMYAÓ: FOKOZÁSÁRA Szab»(hi 1 ntl igénypot) f «k J.aftfely antigénhez,it^tnano^nbçK vagy a«Őgét«· vagylítruttönogént:t»r$a!ro»zô ImofeÄoz konjugàît pepiidet tartalmaz, ahol n pepdd SEQ ID NO: 8, 9. 12, 13, 16, 17, 19-2.4, 151-158, 163-t 66. 168, Î 7:2-i?6, 179-182, Î 85- I 97, i 98-208 és 2 1 0-2 i 6 ï/erir.ii atîriaosav^^y.ek veîiclâk bármelyikéből álkésahof az antigén, immtmogén vagy az: antigént vagy immunogént tártálmázé hordozó a peptíü C-iermináHsához konjugáíl. 2. A?. I. igénypont szerinti fconjugâtumFÂd & ^ptlidiiëï:: a SEQ ID HO: 12, Π. 16, 17 cs 19-24 szerinti anuuosav-szekvenciák bármelyike alkotja. À 2- Igénypont szerinti konjugátum. ahol a pepttd a SEQ ID NO:2a szerinti aminosav-szekverteiéből ál],
  2. 4, Ag: i-3. igénypontok bármelyike szét inti konjugátum, ahol az antigénhez. immöbopÄg vggy a» ántg géht: vafyJïOttjanogéHt tartalmazó hotdozóhoz 2-20 popod kötődik.
  3. 5, Az 1.-4. igénypontok bármelyike szerinti: konjugáíutn. ahol: tsz antigéo vagy ínmuöíögÉi: flmtőmniigén vagy tamotit»«iöö6gén. vagy paíngébisiijgén vagy pat< >gen imnmoogéu.
  4. 6, Az 1:-1. igénypontok bármelyiké szermti koitjogátum gyógyszerként tór.eno «dkuimvs/Aira.
  5. 7, Az: 1-1. Igéíxvp^^Sők’ al^üSÜ^;. £§&amp;: llAgf Jfertözö betegség megelőzésé-ben vagy kezelésében történő alkalmazást».
  6. 8, Ak 1-1, igébypöiitök bámtelyike szénáit rnegelŐzöséfe vagy kezelésére szolgáló gyógyszer előállítására, fl M ? igénypont sgérind kftojngáturn vagy a S. jgéőypbnt szerinti alkalmazás, ahöí az alanynak van téia-nusrzioxtn vagy telanmtztoxoid sileai ellenanyaga. |0. A 7, igénypt»AF^Hhtlkoxtj«gâiMm:iyagy a 8, igénypont szerinti alkalmazás;,; abíÓ Jz alany olyan alany, akíttek a komugáinm beadása előtt legalább kél héttel tefanuszSoxin elleni, keringő ellenanyagok képzésére szollá íő oltóanyagot adiak be. H. A ?. igényporti szedni) keítjugáliu wtgs a 8 mène pont szeneit akahnizas ahol a )et tozo b^Ugsvg vitális, bakteriális, gomba- vagy parazitás betegség. 12. A 7 igénypont szeríttri kunjugátnm vagy a 8. igénypont szerinti pznl választott: ttklö-, vastágMh nyelőé#-, petefészek-, hasnyálmirigy-. bőr-, gyomon-, fej- és Hpk|Í.o{yag-rák, szarkóma, proszkua-, líépaíoeelteláns. agy-, adrenáhs, emlő-, eMörnelriális rák, mezotetíómá, vese^, mirigy-, hematológiai, kardnoki rák, melanoma, mellékpajzsmirigy-, méhnyakrák, nettroblaszióms, Wiims-tumor, hererák, hipofizísrák vagy íeokromociíóma.
  7. 13. Peptid, amely SEQ ID NO: 8. <>, 12. 13, ló, 17, 19-24, 151-158, 163-1őő, 168, 172-176. 179-182. 185. p?* 198-208 és 210-216 szerinfi aptinosav-szekveneiak bárőielylkéböliíí, 14. A 13, igén>£ő«tSä^«&amp;$bpf«k.;ptely SEQ ÍD MO: 2|, 13,46, 1? és f9-24 szériáit atninosay-szefe-vendák bármelyikéből áll. 15. A 14. Igénypont szerinti pepiid, amely SEQ SD NO; 8.mfeos«y**lsékvendiÜ#14Í&amp;
HUE11712343A 2010-03-15 2011-03-15 Peptidek, konjugátumok és eljárás oltóanyag immunogenitásának fokozására HUE031924T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10156505 2010-03-15
US31793010P 2010-03-26 2010-03-26

Publications (1)

Publication Number Publication Date
HUE031924T2 true HUE031924T2 (hu) 2017-08-28

Family

ID=43430699

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11712343A HUE031924T2 (hu) 2010-03-15 2011-03-15 Peptidek, konjugátumok és eljárás oltóanyag immunogenitásának fokozására

Country Status (15)

Country Link
US (1) US9522962B2 (hu)
EP (1) EP2547364B1 (hu)
CN (1) CN102892431A (hu)
CA (1) CA2793087C (hu)
CY (1) CY1118801T1 (hu)
DK (1) DK2547364T3 (hu)
ES (1) ES2616258T3 (hu)
HR (1) HRP20170251T1 (hu)
HU (1) HUE031924T2 (hu)
LT (1) LT2547364T (hu)
PL (1) PL2547364T3 (hu)
PT (1) PT2547364T (hu)
RS (1) RS55670B1 (hu)
SI (1) SI2547364T1 (hu)
WO (1) WO2011115483A1 (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014111724A1 (en) 2013-01-18 2014-07-24 London School Of Hygiene And Tropical Medicine Glycosylation method
GB201301085D0 (en) * 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
CA2943334A1 (en) * 2014-03-19 2015-09-24 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
CN106986923B (zh) * 2017-04-10 2021-01-26 新疆农垦科学院 GnRH抗原及其在主动免疫对公牛的去势效果及肉品质影响中的应用
KR20200143422A (ko) 2018-04-10 2020-12-23 에이씨 이뮨 에스.에이. 항-aveta 치료적 백신
BR112021001520A2 (pt) * 2018-07-31 2021-04-20 Snoretox Pty Ltd neurotoxinas tetânicas peguiladas e tratamento de hipotonia
KR20210095891A (ko) 2018-11-23 2021-08-03 스트라이크 파마 아베 이중 특이적 접합체
GB201917699D0 (en) 2019-12-04 2020-01-15 Ultimovacs Ab Vaccine conjugates
US20230057367A1 (en) * 2020-02-03 2023-02-23 Snoretox Ltd Composition and method
CN113318225B (zh) * 2020-02-28 2024-01-19 无锡派列博生物医药科技有限公司 肿瘤免疫增强剂及其制法和应用
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
US20220118079A1 (en) * 2020-10-20 2022-04-21 Longhorn Vaccines And Diagnostics, Llc Immunogenic Antigens
WO2022187132A1 (en) * 2021-03-04 2022-09-09 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
WO2022258794A2 (en) * 2021-06-09 2022-12-15 Ultimovacs Ab A conjugate
WO2024121411A1 (en) 2022-12-09 2024-06-13 Strike Pharma Ab Optimized tag moiety
WO2024126758A2 (en) 2022-12-14 2024-06-20 Ultimovacs Ab A nucleic acid molecule and a chimeric polypeptide
WO2024126737A1 (en) 2022-12-14 2024-06-20 Ultimovacs Ab A core and a conjugate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
AU693437B2 (en) * 1993-12-28 1998-07-02 Chiron Mimotopes Pty Ltd T-cell epitopes
DE69731357T2 (de) * 1996-03-23 2006-02-02 The Research Foundation For Microbial Diseases Of Osaka University, Suita Funktionelles antigenfragment von tetanustoxin und tetanusvakzine
ES2257771T3 (es) 1996-10-28 2006-08-01 Amersham Health As Agentes de contraste.
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
FR2806727A1 (fr) * 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
AU2002219711B8 (en) 2000-12-08 2006-03-02 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
US20040101534A1 (en) 2002-06-25 2004-05-27 Diamond Don J. Adjuvant-free peptide vaccine
WO2008118487A2 (en) 2007-03-26 2008-10-02 University Of Massachusetts Medical School Compositions and methods for incresing immunogenicity of glycoprotein vaccines

Also Published As

Publication number Publication date
HRP20170251T1 (hr) 2017-04-21
EP2547364A1 (en) 2013-01-23
DK2547364T3 (en) 2017-02-27
US20130071428A1 (en) 2013-03-21
SI2547364T1 (sl) 2017-05-31
CA2793087A1 (en) 2011-09-22
CA2793087C (en) 2019-07-23
PL2547364T3 (pl) 2017-06-30
RS55670B1 (sr) 2017-06-30
WO2011115483A1 (en) 2011-09-22
LT2547364T (lt) 2017-03-27
US9522962B2 (en) 2016-12-20
CY1118801T1 (el) 2018-01-10
PT2547364T (pt) 2017-02-21
ES2616258T3 (es) 2017-06-12
CN102892431A (zh) 2013-01-23
EP2547364B1 (en) 2016-12-14

Similar Documents

Publication Publication Date Title
DK2547364T3 (en) Peptides, conjugates and methods for increasing the immunogenicity of a vaccine
TWI379839B (en) Aβ immunogenic peptide carrier conjugates and methods of producing same
Niederhafner et al. Peptide dendrimers
TWI355390B (en) Immunogenic peptide carrier conjugates and methods
AU2017203425A1 (en) Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer&#39;s type
Hamley Peptides for vaccine development
US9562070B2 (en) Induction of tumor immunity by variants of folate binding protein
JP2001502658A (ja) 非樹状中心骨格ペプチド担体
KR102077876B1 (ko) Crm197 담체 단백질에 커플링된 hiv gp41 펩티드를 포함하는 면역원성 화합물
BR112019018616A2 (pt) peptídeos e métodos para o tratamento de diabetes
CN113574073A (zh) 针对降钙素基因相关肽(cgrp)的肽免疫原及其用于预防和治疗偏头痛的制剂
JPH05260963A (ja) ペプチド−ポリサッカライド−蛋白質複合体ワクチン
US8748130B2 (en) Human papillomavirus / Ii-Key hybrids and methods of use
JP7050807B2 (ja) 新規ペプチドベースのpcsk9ワクチン
WO2018085488A1 (en) Universal mammalian influenza vaccine
TWI823051B (zh) 針對垂體腺苷酸環化酶激活胜肽的胜肽免疫原及其預防和治療偏頭痛的製劑
FR2842812A1 (fr) Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une reponse de type ctl antitumorale ou anti-infectueuse
FR2842811A1 (fr) Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une reponse de type ctl antitumorale ou anti-infectueuse